Molecular Imaging Techniques to Monitor NK Cells in Vivo in a Preclinical and Clinical Scenario
Main Article Content
Abstract
In recent years, the use of natural killer (NK) -based immunotherapy has shown promising measures against various cancers. The therapeutic efficacy of NK cell immunotherapy depends to some extent on the migration of NK cells and subsequent infiltration into tumours in animal models or in humans. The continuous improvement of the healing and therapeutic properties of NK cells stimulates the performance and use of immunotherapy based on NK cells. In this review, we summarize the molecular imaging techniques used to monitor NK cell migration and infiltration in vivo, both preclinical and clinically. The advantages and disadvantages of each molecular imaging modality are considered. Finally, we present our understanding of the use of molecular imaging techniques to monitor NK cells in vivo in a preclinical and clinical scenario.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
IJCERT Policy:
The published work presented in this paper is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This means that the content of this paper can be shared, copied, and redistributed in any medium or format, as long as the original author is properly attributed. Additionally, any derivative works based on this paper must also be licensed under the same terms. This licensing agreement allows for broad dissemination and use of the work while maintaining the author's rights and recognition.
By submitting this paper to IJCERT, the author(s) agree to these licensing terms and confirm that the work is original and does not infringe on any third-party copyright or intellectual property rights.
References
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30. [CrossRef] [PubMed]
Hugosson, J.; Carlsson, S. Overdetection in screening for prostate cancer. Curr. Opin. Urol. 2014, 24, 256–263. [CrossRef] [PubMed]
Schröder, F.H.; Hugosson, J.; Roobol, M.J.; Tammela, T.L.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360, 1320–1328. [CrossRef] [PubMed]
Oberlin, D.T.; Casalino, D.D.; Miller, F.H.; Meeks, J.J. Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. Abdom. Radiol. (Ny) 2017, 42, 1255– 1258. [CrossRef] [PubMed]
Monni, F.; Fontanella, P.; Grasso, A.;Wiklund, P.; Ou, Y.C.; Randazzo, M.; Rocco, B.; Montanari, E.; Bianchi, G.Magnetic resonance imaging in prostate cancer detection and management: A systematic review. Minerva. Urol. Nefrol. 2017, 69, 567–578. [CrossRef] [PubMed]
Vitale, M.; Cantoni, C.; Pietra, G.; Mingari, M.C.; Moretta, L. Effect of tumour cells and tumour microenvironment on NK-cell function. Eur. J. Immunol. 2014, 44, 1582–1592. [CrossRef]
Vanherberghen, B.; Olofsson, P.E.; Forslund, E.; Sternberg-Simon, M.; Khorshidi, M.A.; Pacouret, S.; Guldevall, K.; Enqvist, M.; Malmberg, K.-J.; Mehr, R.; et al. Classification of human natural killer cells based on migration behaviour and cytotoxic response. Blood 2013, 121, 1326–1334. [CrossRef]
Gong, J.H.; Maki, G.; Klingemann, H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8, 652–658.
Dahlberg, C.I.M.; Sarhan, D.; Chrobok, M.; Duru, A.D.; Alici, E. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front. Immunol. 2015, 6. [CrossRef]
Rezvani, K.; Rouce, R.H. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front. Immunol. 2015, 6. [CrossRef]
Garrod, K.R.; Wei, S.H.; Parker, I.; Cahalan, M.D. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targets. Proc. Natl. Acad. Sci. USA 2007, 104, 12081–12086. [CrossRef]
Fang, F.; Xiao, W.; Tian, Z. NK cell-based immunotherapy for cancer. Semin. Immunol. 2017. [CrossRef] [PubMed]
Lee, B.J.; Mace, E.M. Acquisition of cell migration defines NK cell differentiation from hematopoietic stem cell precursors. bioRxiv 2017, 142380. [CrossRef]
Somersalo, K.; Saksela, E. Fibronectin facilitates the migration of human natural killer cells. Eur. J. Immunol.1991, 21, 35–42. [CrossRef]
Taub, D.D.; Sayers, T.J.; Carter, C.R.; Ortaldo, J.R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 1995, 155, 3877–3888